Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smoking rates point to promoting cessation

This article was originally published in The Tan Sheet

Executive Summary

Research showing smoking rates of U.S. adults are not declining could elevate FDA's authority to approve smoking-cessation products under the tobacco control act. The Centers for Disease Control and Prevention Nov. 13 said data from the 2008 National Health Interview Survey show little to no change in smoking rates in the past five years. The study found 46 million U.S. people (20.6 percent) were smokers in 2008, essentially the same as the 2004 rate of 20.9 percent. The Family Smoking Prevention and Tobacco Control Act directs FDA to consider changing the way it reviews smoking cessation products, which would allow the agency to create opportunities for new products and expand markets for existing products (1"The Tan Sheet" Sept. 7, 2009)

You may also be interested in...



Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation

The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Topics

UsernamePublicRestriction

Register

PS103535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel